Portfolio prioritization and optimization

Less than 1 min read

Case study, Commercial, Portfolio, Licensing & Development

Scroll

The challenge

A clinical-stage biopharmaceutical company sought to develop an optimized portfolio strategy. It sought Putnam’s guidance to prioritize asset-level strategies through a holistic review of options.

Our solution

We generated a comprehensive list of asset opportunities and portfolio options and prioritized 18 programs by applying pre-agreed criteria, defining the value of each opportunity, creating revenue streams with market criteria, and facilitating working sessions to align on critical assumptions.

The results

Our portfolio recommendations addressed the enterprise goals of being best-in-class, maximizing economic value, achieving optimal timing, and minimizing risk over time and across geographies.

Insights

More insights.

See all insights

CNS indication/ Endpoint prioritization

A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize...

Medical Affairs omnichannel platform

A large biopharma client objective aimed to optimize its omnichannel (OC) approach for HCP and patient Medical Education...

Rare respiratory claims data analysis

A top biopharma client wanted to understand diagnosis and treatment patterns for a rare respiratory disease only recently associated as a sequela....

Centers of Excellence

AI at Putnam

Open roles